CA EIC Ad
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH SEARCH RESULT
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 2007; 57:43-66
doi: 10.3322/canjclin.57.1.43
© 2007 American Cancer Society
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Freely available
Right arrow Submit a Comment to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when Comments are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jemal, A.
Right arrow Articles by Thun, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jemal, A.
Right arrow Articles by Thun, M. J.

Cancer Statistics, 2007

Ahmedin Jemal, DVM,PhD, Rebecca Siegel, MPH, Elizabeth Ward, PhD, Taylor Murray, Jiaquan Xu and Michael J. Thun, MD,MS

Dr. Jemal is Strategic Director, Cancer Occurrence, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Ms. Siegel is Manager, Surveillance Information Services, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Ward is Managing Director, Surveillance Research, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Mr. Murray is Manager, Surveillance Data Systems, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Mr. Xu is Analyst, Mortality Statistics Branch, Division of Vital Statistics, Centers for Disease Control and Prevention, Hyattsville, MD.
Dr. Thun is Vice President, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.

This article is available online at http://CAonline.AmCancerSoc.org


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 SELECTED FINDINGS
 CANCER OCCURRENCE BY...
 CANCER IN CHILDREN
 LIMITATIONS AND FUTURE...
 REFERENCES
 
Each year, the American Cancer Society (ACS) estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. This report considers incidence data through 2003 and mortality data through 2004. Incidence and death rates are age-standardized to the 2000 US standard million population. A total of 1,444,920 new cancer cases and 559,650 deaths for cancers are projected to occur in the United States in 2007. Notable trends in cancer incidence and mortality rates include stabilization of the age-standardized, delay-adjusted incidence rates for all cancers combined in men from 1995 through 2003; a continuing increase in the incidence rate by 0.3% per year in women; and a 13.6% total decrease in age-standardized cancer death rates among men and women combined between 1991 and 2004. This report also examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, geographic area, and calendar year, as well as the proportionate contribution of selected sites to the overall trends. While the absolute number of cancer deaths decreased for the second consecutive year in the United States (by more than 3,000 from 2003 to 2004) and much progress has been made in reducing mortality rates and improving survival, cancer still accounts for more deaths than heart disease in persons under age 85 years. Further progress can be accelerated by supporting new discoveries and by applying existing cancer control knowledge across all segments of the population.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 SELECTED FINDINGS
 CANCER OCCURRENCE BY...
 CANCER IN CHILDREN
 LIMITATIONS AND FUTURE...
 REFERENCES
 
Cancer is a major public health problem in the United States and other developed countries. Currently, one in four deaths in the United States is due to cancer. In this article, we provide an overview of cancer statistics, including updated incidence, mortality, and survival rates, and expected number of new cancer cases and deaths in 2007.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
SELECTED FINDINGS
 CANCER OCCURRENCE BY...
 CANCER IN CHILDREN
 LIMITATIONS AND FUTURE...
 REFERENCES
 
    Data Sources
Mortality data from 1930 to 2004 in the United States were obtained from the National Center for Health Statistics (NCHS).1 Incidence data for long-term trends (1975 to 2003), 5-year relative survival rates, and data on lifetime probability of developing cancer were obtained from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute, covering about 26% of the US population.2,3,4,5 Incidence data (1995 to 2003) for projecting new cancer cases were obtained from cancer registries that participate in the SEER program or the Centers for Disease Control and Prevention (CDC)'s National Program of Cancer Registries (NPCR), through the North American Associations of Central Cancer Registries (NAACCR). State-specific incidence rates were abstracted from Cancer in North America (1999–2003) Volume One,6 based on data collected by cancer registries participating in the SEER program and NPCR. Population data were obtained from the US Census Bureau.7 Causes of death were coded and classified according to the International Classification of Diseases (ICD-8, ICD-9, and ICD-10).8,9,10 Cancer cases were classified according to the International Classification of Diseases for Oncology.11

    Estimated New Cancer Cases
The precise number of cancer cases diagnosed each year in the nation and in every state is unknown because complete cancer registration has not yet been achieved in some states. Since the American Cancer Society (ACS) began producing estimates of new cancer cases in the current year, the method has been refined several times to take advantage of improvements in data and statistical methods. Beginning with 2007, we are using a new projection method described by Pickle et al12 in an accompanying article inthis issue of CA. The new method is a spatio-temporal model based on incidence data from 1995 through 2003 from 41 states that met NAACCR's high-quality data standard for incidence, covering about 86% of the US population. This contrasts with the previous quadratic autoregressive model based on incidence data from the nine oldest SEER registries, covering about 10% of the US population. Furthermore, the new method considers geographic variations in socio-demographic and lifestyle factors, medical settings, and cancer screening behaviors as predictors of incidence, and accounts for expected delays in case reporting.

    Estimated Cancer Deaths
We used the state-space prediction method13 to estimate the number of cancer deaths expected to occur in the United States and in each state in the year 2007. Projections are based on underlying cause-of-death from death certificates as reported to the NCHS.1 This model projects the number of cancer deaths expected to occur in 2007 based on the number that occurred each year from 1969 to 2004 in the United States and in each state separately.

    Other Statistics
We provide mortality statistics for the leading causes of death as well as deaths from cancer in the year 2004. Causes of death for 2004 were coded and classified according to ICD-10.8 This report also provides updated statistics on trends in cancer incidence and mortality rates, the probability of developing cancer, and 5-year relative survival rates for selected cancer sites based on data from 1975 through 2003.3 All age-adjusted incidence and death rates are standardized to the 2000 US standard population and expressed per 100,000 population.

The long-term incidence rates and trends (1975 to 2003) are adjusted for delays in reporting where possible. Delayed reporting affects the most recent 1 to 3 years of incidence data (in this case, 2001 to 2003), especially for cancers such as melanoma and prostate that are frequently diagnosed in outpatient settings. The National Cancer Institute (NCI) has developed a method to account for expected reporting delays in SEER registries for all cancer sites combined and several specific cancer sites when long-term incidence trends are analyzed.14 Delay-adjusted trends provide a more accurate assessment of trends in the most recent years for which data are available.


   SELECTED FINDINGS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 SELECTED FINDINGS
CANCER OCCURRENCE BY...
 CANCER IN CHILDREN
 LIMITATIONS AND FUTURE...
 REFERENCES
 
    Expected Numbers of New Cancer Cases
Table 1 presents estimated numbers of new cases of invasive cancer expected among men and women in the United States in 2007. The overall estimate of about 1.44 million new cases does not include carcinoma in situ of any site except urinary bladder, nor does it include basal cell and squamous cell cancers of the skin. More than 1 million additional cases of basal cell and squamous cell skin cancer, about 62,030 cases of breast carcinoma in situ, and 48,290 cases of in situ melanoma are expected to be newly diagnosed in 2007. Because of the introduction of a new projection method, estimates have been affected for many individual cancer sites, particularly for leukemia, female breast, lung, and prostate cancers. The estimated numbers of new cancer cases for each state and selected cancer sites are shown in Table 2.


View this table:
[in this window]
[in a new window]

  		TABLE 1 Estimated New Cancer Cases and Deaths by Sex, US, 2007*

 

View this table:
[in this window]
[in a new window]

  		TABLE 2 Age-standardized Incidence Rates for All Cancers Combined, 1999-2003, and Estimated New Cases* for Selected Cancers by State, US, 2007

 
Figure 1 indicates the most common cancers expected to occur in men and women in 2007. Among men, cancers of the prostate, lung and bronchus, and colon and rectum account for about 54% of all newly diagnosed cancers. Prostate cancer alone accounts for about 29% (218,890) of incident cases in men. Based on cases diagnosed between 1996 and 2002, an estimated 91% of these new cases of prostate cancer are expected to be diagnosed at local or regional stages, for which 5-year relative survival approaches 100%.


Figure 1
View larger version (28K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 1 Ten Leading Cancer Types for the Estimated New Cancer Cases and Deaths, by Sex, US, 2007.

*Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder. Estimates are rounded to the nearest 10.

 
The three most commonly diagnosed types of cancer among women in 2007 will be cancers of the breast, lung and bronchus, and colon and rectum, accounting for about 52% of estimated cancer cases in women. Breast cancer alone is expected to account for 26% (178,480) of all new cancer cases among women.

    Expected Number of New Cancer Deaths
Table 1 also shows the expected number of deaths from cancer projected for 2007 for men, women, and both sexes combined. It is estimated that about 559,650 Americans will die from cancer, corresponding to over 1,500 deaths per day. Cancers of the lung and bronchus, prostate, and colon and rectum in men, and cancers of the lung and bronchus, breast, and colon and rectum in women continue to be the most common fatal cancers. These four cancers account for half of the total cancer deaths among men and women (Figure 1). Lung cancer surpassed breast cancer as the leading cause of cancer death in women in 1987. Lung cancer is expected to account for 26% of all female cancer deaths in 2007. Table 3 provides the estimated number of cancer deaths in 2007 by state for selected cancer sites.


View this table:
[in this window]
[in a new window]

  		TABLE 3 Age-standardized Death Rates for All Cancers Combined, 1999-2003, and Estimated Deaths* From All Cancers Combined and Selected Sites by State, US, 2007

 
    Regional Variations in Cancer Rates
Table 4 depicts cancer incidence for select cancers by state. Rates vary widely across states. For example, among the cancers listed in Table 4, the largest variations in the incidence rates, in proportionate terms, occurred in lung cancer, in which rates (cases per 100,000 population) ranged from 41.8 in men and 21.5 in women in Utah to 137.9 in men and 73.5 in women in Kentucky. In contrast, the variation in female breast cancer incidence rates was small, ranging from 115 cases per 100,000 population in New Mexico to 146.7 cases in Washington. Factors that contribute to the state variations in the incidence rates include differences in the prevalence of risk factors, access to and utilization of early detection services, and completeness of reporting. For example, the state variation in lung cancer incidence rates primarily reflects differences in smoking prevalence; Utah ranks lowest in adult smoking prevalence and Kentucky highest.


View this table:
[in this window]
[in a new window]

  		TABLE 4 Cancer Incidence Rates* by Site and State, US, 1999 to 2003

 
    Trends in Cancer Incidence and Mortality
Figures 2GoGo to 5 depict long-term trends in cancer incidence and death rates for all cancers combined and for selected cancer sites by sex. Table 5 shows incidence and mortality patterns for all cancer sites combined and for the four most common cancer sites based on joinpoint analysis. Trends in incidence were adjusted for delayed reporting. Delay-adjusted cancer incidence rates for all sites combined stabilized in men from 1995 to 2003 and increased in women by 0.3% per year from 1987 to 2003.


Figure 2
View larger version (18K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 2 Annual Age-adjusted Cancer Incidence and Death Rates* for All Sites, by Sex, US, 1975 to 2003.

*Rates are age-adjusted to the 2000 US standard population. Incidence rates are adjusted for delays in reporting. Source: Incidence—Surveillance, Epidemiology, and End Results (SEER) program, (www.seer.cancer.gov). Delay-Adjusted Incidence database: "SEER Incidence Delay-Adjusted Rates, 9 Registries, 1975–2003." National Cancer Institute, DCCPS, Surveillance Research Program, Statistical Research and Applications Branch, released April 2006, based on the November 2005 SEER data submission. Mortality—US Mortality Public Use Data Tapes, 1960 to 2003, National Center for Health Statistics, Centers for Disease Control and Prevention, 2006.

 

Figure 3
View larger version (26K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 3 Annual Age-adjusted Cancer Incidence Rates* Among Males and Females for Selected Cancers, US, 1975 to 2003.

*Rates are age-adjusted to the 2000 US standard population and adjusted for delays in reporting. Source: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). Delay-Adjusted Incidence database: "SEER Incidence Delay-Adjusted Rates, 9 Registries, 1975–2003." National Cancer Institute, DCCPS, Surveillance Research Program, Statistical Research and Applications Branch, released April 2006, based on the November 2005 SEER data submission.

 

Figure 4
View larger version (21K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 4 Annual Age-adjusted Cancer Death Rates*

*Among Males for Selected Cancers, US, 1930 to 2003. *Rates are age-adjusted to the 2000 US standard population. Note: Due to changes in ICD coding, numerator information has changed over time. Rates for cancers of the lung and bronchus, colon and rectum, and liver are affected by these changes. Source: US Mortality Public Use Data Tapes, 1960 to 2003, US Mortality Volumes, 1930 to 1959, National Center for Health Statistics, Centers for Disease Control and Prevention, 2006.

 

Figure 5
View larger version (19K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 5 Annual Age-adjusted Cancer Death Rates* Among Females for Selected Cancers, US, 1930 to 2003.

*Rates are age-adjusted to the 2000 US standard population.

{dagger}Uterus includes uterine cervix and uterine corpus.

Note: Due to changes in ICD coding, numerator information has changed over time. Rates for cancers of the uterus, ovary, lung and bronchus, and colon and rectum are affected by these changes. Source: US Mortality Public Use Data Tapes, 1960 to 2003, US Mortality Volumes 1930 to 1959, National Center for Health Statistics, Centers for Disease Control and Prevention, 2006.

 

View this table:
[in this window]
[in a new window]

  		TABLE 5 Trends in Cancer Incidence and Death Rates for Selected Cancers by Sex, US, 1975 to 2003

 
Lung cancer incidence rates are declining in men and appear to be plateauing in women after increasing for many decades. The lag in the temporal trend of lung cancer incidence rates in women compared with men reflects historical differences in cigarette smoking between men and women; cigarette smoking in women peaked about 20 years later than in men. Colorectal cancer incidence rates have decreased from 1998 through 2003 in both males and in females. Female breast cancer incidence rates leveled off from 2001 to 2003 after increasing since 1980, which may reflect the saturation of mammography utilization and reduction in the use of hormone replacement therapy.15 Prostate cancer incidence rates continued to increase, although at a slower rate than those reported for the early 1990s and before. The continuing increase for prostate cancer may be attributable to increased screening through prostate-specific antigen (PSA) testing.15

Death rates for all cancer sites combined decreased by 1.6% per year from 1993 to 2003 in males and by 0.8% per year in females from 1992 to 2003. Mortality rates have continued to decrease across all four major cancer sites in men and in women, except for female lung cancer in which rates continued to increase by 0.3% per year from 1995 to 2003 (Table 5).

Table 6 shows the contribution of individual cancer sites to the total decrease in overall cancer death rates. Death rates from all cancers combined peaked in 1990 for men and in 1991 for women. Between 1990/1991 and 2003, death rates from cancer decreased by 16.3% among men and by 8.5% among women. Among men, reduction in death rates from lung, prostate, and colorectal cancers accounts for about 80% of the decrease in cancer death rates, while reduction in death rates from breast and colorectal cancers accounts for over 60% of the decrease among women. Lung cancer in men and breast cancer in women alone account for nearly 40% of the sex-specific decreases in cancer death rates. The decrease in lung cancer death rates among men is due to reduction in tobacco use over the past 40 years, while the decrease in death rates from female breast, colorectal, and prostate cancer largely reflects improvements in early detection and treatment. Between 1990/1991 and 2003, death rates increased substantially for lung cancer in women and for liver and intrahepatic bile duct cancer in men.


View this table:
[in this window]
[in a new window]

  		TABLE 6 The Contribution of Indvidual Cancer Sites to the Decrease in Cancer Death Rates, 1990–2003

 
    Changes in the Recorded Number of DeathsFrom Cancer From 2003 to 2004
A total of 553,888 cancer deaths was recorded in the United States in 2004, the most recent year for which actual data are available. There were 3,014 fewer cancer deaths reported in 2004 than in 2003, resulting in a decrease in the total number of cancer deaths for the second consecutive year. Cancer accounted for about 23% of all deaths, ranking second only to heart disease (Table 7). When cause of death is ranked within each age group, categorized in 20-year age intervals, cancer is one of the five leading causes of death in each age group among both males and females (Table 8). Cancer is the leading cause of death among women aged 40 to 79 years and among men aged 60 to 79 years. When age-adjusted death rates are considered (Figure 6), cancer is the leading cause of death among men and women under age 85 years. A total of 473,535 people under age 85 years died from cancer in the United States in 2004, compared with 414,526 deaths from heart disease.


View this table:
[in this window]
[in a new window]

  		TABLE 7 Fifteen Leading Causes of Death, US, 2004

 

View this table:
[in this window]
[in a new window]

  		TABLE 8 Ten Leading Causes of Death by Age and Sex, US, 2004

 

Figure 6
View larger version (18K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 6 Death Rates* From Cancer and Heart Disease for Ages Younger Than 85 and 85 and Older.

*Rates are age-adjusted to the 2000 US standard population.

Source: US Mortality Public Use Data Tapes, 1960 to 2003, National Center for Health Statistics, Centers for Disease Control and Prevention, 2006.

 
Table 9 presents the number of deaths from all cancers combined and the five most common cancer sites for males and females at various ages. Among males under age 40 years, leukemia is the most common fatal cancer, while cancer of the lung and bronchus predominates in men aged 40 years and older. The second most common cause of cancer death is colorectal cancer among men aged 40 to 79 years and prostate cancer among men aged 80 years and older. Among females, leukemia is the leading cause of cancer death before age 20 years, breast cancer ranks first at age 20 to 59 years, and lung cancer ranks first at age 60 years and older.


View this table:
[in this window]
[in a new window]

  		TABLE 9 Reported Deaths for the Five Leading Cancer Sites by Age and Sex, US, 2004

 
From 2003 to 2004, the number of recorded cancer deaths decreased by 1,160 in men and by 1,854 in women (Table 10). The largest change in number of deaths from the major cancers was for colorectal cancer in both men and women (decreased by 1,110 and 1,094, respectively).


View this table:
[in this window]
[in a new window]

  		TABLE 10 Trends in the Recorded Number of Deaths for Selected Cancers by Sex, US, 1989 to 2004

 

   CANCER OCCURRENCE BY RACE/ETHNICITY
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 SELECTED FINDINGS
 CANCER OCCURRENCE BY...
CANCER IN CHILDREN
 LIMITATIONS AND FUTURE...
 REFERENCES
 
Cancer incidence and death rates vary considerably among racial and ethnic groups (Table 11). For all cancer sites combined, African American men have a 15% higher incidence rate and 38% higher death rate than White men. African American women have a 9% lower incidence rate, but an 18% higher death rate than White women for all cancer sites combined. For the specific cancer sites listed in Table 11, incidence and death rates are consistently higher in African Americans than in Whites, except for breast cancer (incidence) and lung and kidney cancers (incidence and mortality) among women. Death rates from prostate, stomach, and cervical cancers among African Americans are more than twice those in Whites. Factors known to contribute to racial disparities in mortality vary by cancer site. These factors include differences in exposure to underlying risk factors (eg, Helicobacter pylori for stomach cancer), access to high-quality regular screening (breast, cervical, and colorectal cancers), and timely diagnosis and treatment (for many cancers). The higher breast cancer incidence rates among Whites are thought to reflect a combination of factors that affect diagnosis (such as more frequent mammography in White women until the most recent time period) and those that affect disease risk (such as later age at first birth and greater use of hormone replacement therapy among White than African American women).16


View this table:
[in this window]
[in a new window]

  		TABLE 11 Incidence and Death Rates* for Selected Cancers by Race and Ethnicity, US, 1999 to 2003

 
Among other racial and ethnic groups, cancer incidence and death rates are lower than those in Whites and African Americans for all cancer sites combined and for the four most common cancer sites. However, the incidence and death rates are generally higher in minority populations than in Whites for cancers of the uterine cervix, stomach, and liver. Stomach and liver cancer incidence and death rates are more than twice as high in Asian American/Pacific Islanders as in Whites, reflecting increased exposure to infectious agents such as Helicobacter pylori and hepatitis B.17 Kidney cancer incidence and death rates are the highest among American Indians/Alaskan Natives, although factors that contribute to this are unknown.

Trends in cancer incidence can only be adjusted for delayed reporting in Whites and African Americans, and not in other racial and ethnic subgroups, because long-term incidence data required for delay adjustment are available only for Whites and African Americans. From 1995 to 2003, sex-specific incidence rates for all cancer sites combined, not adjusted for delayed reporting, have stabilized, except for African American and Hispanic men, in whom rates decreased by 1.3% and 1.1%, respectively. In contrast, death rates from cancer significantly decreased in each racial and ethnic group, with larger decreases in men than in women.3

    Lifetime Probability of Developing Cancer
The lifetime probability of developing cancer is higher for men (45%) than for women (38%) (Table 12). However, because of the relatively early age of breast cancer onset, women have a slightly higher probability of developing cancer before age 60 years. It is noteworthy that these estimates are based on the average experience of the general population and may over- or underestimate individual risk because of differences in exposure and/or genetic susceptibility.


View this table:
[in this window]
[in a new window]

  		TABLE 12 Probability of Developing Invasive Cancers Within Selected Age Intervals, by Sex, US*

 
    Cancer Survival by Race
Compared with Whites, African American men and women have poorer survival once a cancer diagnosis is made. As shown in Figure 7, African Americans are less likely than Whites to be diagnosed with cancer at a localized stage, when the disease may be more easily and successfully treated, and are more likely to be diagnosed with cancer at a regional or distant stage of disease. Five-year relative survival is lower in African Americans than Whites within each stratum of stage of diagnosis for nearly every cancer site (Figure 8). These disparities may result from inequalities in access to and receipt of quality health care and/or within-stage differences in tumor characteristics. The contribution of these factors, individually or collectively, to the differential survival for specific cancers is unclear.18 However, some studies suggest that African Americans who receive cancer treatment and medical care similar to that of Whites experience similar outcomes.19


Figure 7
View larger version (29K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 7 Distribution of Selected Cancers by Race and Stage at Diagnosis, US, 1996–2002.

*The distribution for localized stage represents localized and regional stages combined.

Note: Staging according to Surveillance, Epidemiology, and End Results (SEER) historic stage categories rather than the American Joint Committee on Cancer (AJCC) staging system. For each cancer type, stage categories do not total 100% because sufficient information is not available to assign a stage to all cancer cases. Comparison of this data to that of previous years is discouraged due to the use of an expanded data set.

Source: Ries LAG, Harkins D, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975–2003, National Cancer Institute, based on November 2005 SEER data submission, posted to the SEER Web site, 2006.

 

Figure 8
View larger version (36K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
  		FIGURE 8 Five-year Relative Survival Rates Among Patients Diagnosed With Selected Cancers, by Race and Stage at Diagnosis, US, 1996–2002.

*The rate for localized stage represents localized and regional stages combined. Note: Staging according to Surveillance, Epidemiology, and End Results (SEER) historic stage categories rather than the American Joint Committee on Cancer (AJCC) staging system. Comparison of this data to that of previous years is discouraged due to the use of an expanded data set.

Source: Ries LAG, Harkins D, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975–2003, National Cancer Institute, based on November 2005 SEER data submission, posted to the SEER Web site, 2006.

 
There have been notable improvements over time in relative 5-year survival rates for many cancer sites and for all cancers combined (Table 13). This is true for both Whites and African Americans. Cancers for which survival has not improved substantially over the past 25 years include uterine corpus, cervix, larynx, lung, and pancreas.


View this table:
[in this window]
[in a new window]

  		TABLE 13 Trends in Five-year Relative Survival Rates* (%) for Selected Cancers by Race and Year of Diagnosis, US, 1975 to 2002.

 
Relative survival rates cannot be calculated for other racial and ethnic populations because accurate life expectancies (the average number of years of life remaining for persons who have attained a given age) are not available. However, based on cause-specific survival rates of cancer patients diagnosed from 1992 to 2000 in SEER areas of the United States, all minority populations, except Asian American/Pacific Islander women, have a greater probability of dying from cancer within 5 years of diagnosis than non-Hispanic Whites, after accounting for differences in stage at diagnosis.15,20 For the four major cancer sites (prostate, female breast, lung and bronchus, and colon and rectum), minority populations are more likely to be diagnosed at distant stage, compared with non-Hispanic Whites.20


   CANCER IN CHILDREN
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 SELECTED FINDINGS
 CANCER OCCURRENCE BY...
 CANCER IN CHILDREN
LIMITATIONS AND FUTURE...
 REFERENCES
 
Cancer is the second leading cause of death among children between age 1 to 14 years in the United States; accidents are the most frequent cause of death in this age group (Table 14). The most common cancers in children (aged 0 to 14 years) are leukemia (particularly acute lymphocytic leukemia), brain and other nervous system cancers, soft tissue sarcomas, non-Hodgkin lymphoma, and renal (Wilms) tumors.3 Over the past 25 years, there have been significant improvements in the 5-year relative survival rate for many childhood cancers (Table 15). The 5-year relative survival rate among children for all cancer sites combined improved from 58% for patients diagnosed in 1975 to 1977 to 79% for those diagnosed in 1996 to 2002.3


View this table:
[in this window]
[in a new window]

  		TABLE 14 Fifteen Leading Causes of Death Among Children Aged 1 to 14, US, 2004

 

View this table:
[in this window]
[in a new window]

  		TABLE 15 Trends in Five-year Relative Survival Rates* (%) for Children Under Age 15, US, 1975 to 2002.

 

   LIMITATIONS AND FUTURE CHALLENGES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 SELECTED FINDINGS
 CANCER OCCURRENCE BY...
 CANCER IN CHILDREN
 LIMITATIONS AND FUTURE...
REFERENCES
 
Estimates of the expected numbers of new cancer cases and cancer deaths should be interpreted cautiously. These estimates may vary considerably from year to year, particularly for less common cancers and in states with smaller populations. Unanticipated changes may occur that are not captured by modeling techniques. Estimates are also affected by changes in method. The introduction of a new method for estimating new cancer cases in 2007 has substantially affected the estimates for a number of cancers, particularly leukemia and female breast (see Pickle et al for more detailed discussion).12 For these reasons, we discourage the use of these estimates to track year-to-year changes in cancer occurrence and death. Age-standardized or age-specific cancer death rates from the NCHS and cancer incidence rates from SEER or NPCR are the preferred data sources for tracking cancer trends, even though these data are 3 and 4 years old, respectively, by the time that they become available. Despite their limitations, the ACS estimates of the number of new cancer cases and deaths in the current year provide reasonably accurate estimates of the burden of new cancer cases and deaths in the United States. Such estimates will assist in continuing efforts to reduce the public health burden of cancer.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 SELECTED FINDINGS
 CANCER OCCURRENCE BY...
 CANCER IN CHILDREN
 LIMITATIONS AND FUTURE...
 REFERENCES
 

  1. National Center for Health Statistics, Division of Vital Statistics, Centers for Disease Control. Available at: http://www.cdc.gov/nchs/nvss.htm. Accessed November 22, 2006.
  2. National Cancer Institute, U.S. National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 9 Regs Public-Use, Nov 2005 Sub (1973–2003), Linked to County Attributes, Total US, 1969–2003 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.
  3. Ries LAG, Harkins D, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975–2003, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER Web site, 2006.
  4. National Cancer Institute, U.S. National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 13 Regs Public-Use, Nov 2005 Sub (1992–2003), Linked to County Attributes, Total US, 1969–2003 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.
  5. National Cancer Institute, U.S. National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 17 Regs Public-Use, Nov 2005 Sub (2000–2003), Linked to County Attributes, Total US, 1969–2003 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.
  6. Ellison JH, Wu XC, McLaughlin CC, et al., eds. Cancer in North America, 1999–2003. Volume One: Incidence. Springfield, IL: North American Association of Central Cancer Registries, Inc.; 2006.
  7. US Census Bureau, Population Division, Population Projections Branch. Available at: http://www.census.gov/population/www/projections/popproj.html. Accessed September 15, 2006.
  8. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Vol. 1, 10th revision. Geneva, Switzerland: World Health Organization; 1992.
  9. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Vol. 1, 9th revision. Geneva, Switzerland: World Health Organization; 1975.
  10. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Vol. 1, 8th revision. Geneva, Switzerland: World Health Organization; 1967.
  11. Fritz A, Percy C, Jack A, et al., eds. International Classification of Diseases for Oncology, 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
  12. Pickle LW, Hao Y, Jemal A, et al. A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin 2007;57:30–42.[Abstract/Free Full Text]
  13. Tiwari RC, Ghosh K, Jemal A, et al. A new method of predicting US and state-level cancer mortality counts for the current calendar year. CA Cancer J Clin 2004;54:30–40.[Abstract/Free Full Text]
  14. Clegg LX, Feuer EJ, Midthune DN, et al. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst 2002;94:1537–1545.[Abstract/Free Full Text]
  15. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 2004;101:3–27.[CrossRef][Medline]
  16. Ghafoor A, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity. CA Cancer J Clin 2003;53:342–355.[Abstract/Free Full Text]
  17. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 2004;54:78–93.[Abstract/Free Full Text]
  18. Ghafoor A, Jemal A, Cokkinides V, et al. Cancer statistics for African Americans. CA Cancer J Clin 2002;52:326–341.[Abstract/Free Full Text]
  19. Bach PB, Schrag D, Brawley OW, et al. Survival of blacks and whites after a cancer diagnosis. JAMA 2002;287:2106–2112.[Abstract/Free Full Text]
  20. Clegg LX, Li FP, Hankey BF, et al. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 2002;162:1985–1993.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Roentgenol.Home page
A. O'Connell, D. L. Conover, Y. Zhang, P. Seifert, W. Logan-Young, C.-F. L. Lin, L. Sahler, and R. Ning
Cone-Beam CT for Breast Imaging: Radiation Dose, Breast Coverage, and Image Quality
Am. J. Roentgenol., August 1, 2010; 195(2): 496 - 509.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Fu, E. L. Maresh, R. A. Soslow, M. Alavi, V. Mah, Q. Zhou, A. Iasonos, L. Goodglick, L. K. Gordon, J. Braun, et al.
Epithelial Membrane Protein-2 Is a Novel Therapeutic Target in Ovarian Cancer
Clin. Cancer Res., August 1, 2010; 16(15): 3954 - 3963.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. J. Rickles, L. T. Pierce, T. P. Giordano 3rd, W. F. Tam, D. W. McMillin, J. Delmore, J. P. Laubach, A. A. Borisy, P. G. Richardson, and M. S. Lee
Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies
Blood, July 29, 2010; 116(4): 593 - 602.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Wang, Y. Jin, Y. J. Arnoldussen, I. Jonson, S. Qu, G. M. Maelandsmo, A. Kristian, B. Risberg, H. Waehre, H. E. Danielsen, et al.
STAMP1 Is Both a Proliferative and an Antiapoptotic Factor in Prostate Cancer
Cancer Res., July 15, 2010; 70(14): 5818 - 5828.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. C. Christensen, M. Avissar-Whiting, L. G. Ouellet, R. A. Butler, H. H. Nelson, M. D. McClean, C. J. Marsit, and K. T. Kelsey
Mature MicroRNA Sequence Polymorphism in MIR196A2 Is Associated with Risk and Prognosis of Head and Neck Cancer
Clin. Cancer Res., July 15, 2010; 16(14): 3713 - 3720.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
E. Penn, D. Garrow, and J. Romagnuolo
Influence of Race and Sex on Prevalence and Recurrence of Colon Polyps
Arch Intern Med, July 12, 2010; 170(13): 1127 - 1132.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Q. Lin, M. Li, Z.-Y. Shen, L.-W. Xiong, X.-F. Pan, J.-F. Gen, G.-L. Bao, H.-F. Sha, J.-X. Feng, C.-Y. Ji, et al.
Prognostic Impact of Vascular Endothelial Growth Factor-A and E-Cadherin Expression in Completely Resected Pathologic Stage I Non-Small Cell Lung Cancer
Jpn. J. Clin. Oncol., July 1, 2010; 40(7): 670 - 676.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
C. M. van der Aalst, K. A. M. van den Bergh, M. C. Willemsen, H. J. de Koning, and R. J. van Klaveren
Lung cancer screening and smoking abstinence: 2 year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial
Thorax, July 1, 2010; 65(7): 600 - 605.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
X.-R. Yang, Y. Xu, B. Yu, J. Zhou, S.-J. Qiu, G.-M. Shi, B.-H. Zhang, W.-Z. Wu, Y.-H. Shi, B. Wu, et al.
High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma
Gut, July 1, 2010; 59(7): 953 - 962.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Baumgart, S. Seidl, P. Vlachou, L. Michel, N. Mitova, N. Schatz, K. Specht, I. Koch, T. Schuster, R. Grundler, et al.
ADAM17 Regulates Epidermal Growth Factor Receptor Expression through the Activation of Notch1 in Non-Small Cell Lung Cancer
Cancer Res., July 1, 2010; 70(13): 5368 - 5378.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
E. R. Olson, T. Melton, S. E. Dickinson, Z. Dong, D. S. Alberts, and G. T. Bowden
Quercetin Potentiates UVB-Induced c-Fos Expression: Implications for Its Use as a Chemopreventive Agent
Cancer Prevention Research, July 1, 2010; 3(7): 876 - 884.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. Cykert, P. Dilworth-Anderson, M. H. Monroe, P. Walker, F. R. McGuire, G. Corbie-Smith, L. J. Edwards, and A. J. Bunton
Factors Associated With Decisions to Undergo Surgery Among Patients With Newly Diagnosed Early-Stage Lung Cancer
JAMA, June 16, 2010; 303(23): 2368 - 2376.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Faoro, P. A. Singleton, G. M. Cervantes, F. E. Lennon, N. W. Choong, R. Kanteti, B. D. Ferguson, A. N. Husain, M. S. Tretiakova, N. Ramnath, et al.
EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation
J. Biol. Chem., June 11, 2010; 285(24): 18575 - 18585.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in UrologyHome page
P. Sountoulides, N. Koletsas, D. Kikidakis, K. Paschalidis, and N. Sofikitis
Secondary malignancies following radiotherapy for prostate cancer
Therapeutic Advances in Urology, June 1, 2010; 2(3): 119 - 125.
[Abstract] [PDF]

Home page
 ICVTSHome page
R. Kanzaki, M. Higashiyama, J. Maeda, J. Okami, T. Hosoki, Y. Hasegawa, M. Takami, and K. Kodama
Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients
Interactive CardioVascular and Thoracic Surgery, June 1, 2010; 10(6): 1009 - 1014.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Dai and D. W. Siemann
BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor-Stimulated Prostate Cancer Metastatic Phenotype In vitro
Mol. Cancer Ther., June 1, 2010; 9(6): 1554 - 1561.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. G. Broustas, J. S. Ross, Q. Yang, C. E. Sheehan, R. Riggins, A.-M. Noone, B. R. Haddad, F. Seillier-Moiseiwitsch, B. V. S. Kallakury, B. G. Haffty, et al.
The Proapoptotic Molecule BLID Interacts with Bcl-XL and Its Downregulation in Breast Cancer Correlates with Poor Disease-Free and Overall Survival
Clin. Cancer Res., June 1, 2010; 16(11): 2939 - 2948.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. B. Dorff, B. Goldman, J. K. Pinski, P. C. Mack, P. N. Lara Jr., P. J. Van Veldhuizen Jr., D. I. Quinn, N. J. Vogelzang, I. M. Thompson Jr., and M. H. A. Hussain
Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
Clin. Cancer Res., June 1, 2010; 16(11): 3028 - 3034.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
X. Zhang, B. Han, J. Huang, B. Zheng, Q. Geng, F. Aziz, and Q. Dong
Prognostic Significance of OCT4 Expression in Adenocarcinoma of the Lung
Jpn. J. Clin. Oncol., May 12, 2010; (2010) hyq066v1.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
C. Zhou, S. Ren, S. Zhou, L. Zhang, C. Su, Z. Zhang, Q. Deng, and J. Zhang
Predictive Effects of ERCC1 and XRCC3 SNP on Efficacy of Platinum-based Chemotherapy in Advanced NSCLC Patients
Jpn. J. Clin. Oncol., May 12, 2010; (2010) hyq071v1.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol PractHome page
H. A. Burris III, C. P. Belani, P. A. Kaufman, A. N. Gordon, L. S. Schwartzberg, W. S. Paroly, S. Shahin, L. Dreiling, and A. Saven
Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies
J. Oncol. Pract, May 1, 2010; 6(3): 133 - 140.
[Abstract] [Full Text] [PDF]

Home page
 Acta Biochim Biophys SinHome page
H. Cheng, N. Sun, X. Sun, B. Chen, F. Li, J. Feng, L. Cheng, and Y. Cao
Polymorphisms in hMSH2 and hMLH1 and response to platinum-based chemotherapy in advanced non-small-cell lung cancer patients
Acta Biochim Biophys Sin, May 1, 2010; 42(5): 311 - 317.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. Davidoff, M. Tang, B. Seal, and M. J. Edelman
Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., May 1, 2010; 28(13): 2191 - 2197.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
N. KOHRENHAGEN, H.-U. VOELKER, M. KAPP, J. DIETL, and U. KAMMERER
The Expression of Galectin-1 in Vulvar Neoplasia
Anticancer Res, May 1, 2010; 30(5): 1547 - 1552.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
S. HOLDENRIEDER, J. VON PAWEL, T. DUELL, K. FELDMANN, H. RAITH, A. SCHOLLEN, D. NAGEL, and P. STIEBER
Clinical Relevance of Thymidine Kinase for the Diagnosis, Therapy Monitoring and Prognosis of Non-operable Lung Cancer
Anticancer Res, May 1, 2010; 30(5): 1855 - 1862.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Khalili, L. N. Mutton, B. Gurel, J. L. Hicks, A. M. De Marzo, and C. J. Bieberich
Loss of Nkx3.1 Expression in Bacterial Prostatitis: A Potential Link Between Inflammation and Neoplasia
Am. J. Pathol., May 1, 2010; 176(5): 2259 - 2268.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Xiao and S. V. Singh
p66Shc Is Indispensable for Phenethyl Isothiocyanate-Induced Apoptosis in Human Prostate Cancer Cells
Cancer Res., April 15, 2010; 70(8): 3150 - 3158.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in UrologyHome page
R. Ramanathan and R. J. Leveillee
Ablative therapies for renal tumors
Therapeutic Advances in Urology, April 1, 2010; 2(2): 51 - 68.
[Abstract] [PDF]

Home page
 Jpn J Clin OncolHome page
T. Kawaguchi, M. Sho, T. Tojo, I. Yamato, T. Nomi, K. Hotta, K. Hamada, Y. Suzaki, S. Sugiura, K. Kushibe, et al.
Clinical Significance of Prostate Stem Cell Antigen Expression in Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., April 1, 2010; 40(4): 319 - 326.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
M. R Loebinger and S. M Janes
Stem cells as vectors for antitumour therapy
Thorax, April 1, 2010; 65(4): 362 - 369.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. J. Ruddy, S. Gelber, J. Shin, J. E. Garber, R. Rosenberg, M. Przypysny, and A. H. Partridge
Genetic testing in young women with breast cancer: results from a Web-based survey
Ann. Onc., April 1, 2010; 21(4): 741 - 747.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. P. Dineen, C. L. Roland, R. Greer, J. G. Carbon, J. E. Toombs, P. Gupta, N. Bardeesy, H. Sun, N. Williams, J. D. Minna, et al.
Smac Mimetic Increases Chemotherapy Response and Improves Survival in Mice with Pancreatic Cancer
Cancer Res., April 1, 2010; 70(7): 2852 - 2861.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
L. BLANCO, I. PEREZ, B. SANZ, J. GIL, J. I. LOPEZ, A. UGALDE, A. VARONA, and G. LARRINAGA
Changes in Cell-Surface Peptidase Activity in Papillary Renal Cell Carcinoma
Anticancer Res, April 1, 2010; 30(4): 1137 - 1141.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
C.-J. LIU, T.-C. HSIA, R.-F. WANG, C.-W. TSAI, C.-C. CHU, L.-W. HANG, C.-H. WANG, H.-Z. LEE, R.-Y. TSAI, and D.-T. BAU
Interaction of Cyclooxygenase 2 Genotype and Smoking Habit in Taiwanese Lung Cancer Patients
Anticancer Res, April 1, 2010; 30(4): 1195 - 1199.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. C. du Rieu, J. Torrisani, J. Selves, T. Al Saati, A. Souque, M. Dufresne, G. J. Tsongalis, A. A. Suriawinata, N. Carrere, L. Buscail, et al.
MicroRNA-21 Is Induced Early in Pancreatic Ductal Adenocarcinoma Precursor Lesions
Clin. Chem., April 1, 2010; 56(4): 603 - 612.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. El-Gazzar, P. Perco, E. Eckelhart, M. Anees, V. Sexl, B. Mayer, Y. Liu, W. Mikulits, R. Horvat, T. Pangerl, et al.
Natural Immunity Enhances the Activity of a DR5 Agonistic Antibody and Carboplatin in the Treatment of Ovarian Cancer
Mol. Cancer Ther., April 1, 2010; 9(4): 1007 - 1018.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
J. Zapka, S. H. Taplin, R. Anhang Price, C. Cranos, and R. Yabroff
Factors in Quality Care--The Case of Follow-Up to Abnormal Cancer Screening Tests--Problems in the Steps and Interfaces of Care
J Natl Cancer Inst Monographs, April 1, 2010; 2010(40): 58 - 71.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
I. Okamoto, M. Munakata, M. Miyazaki, T. Satoh, T. Takahata, Y. Takamatsu, O. Muto, K. Koike, K. Ishitani, T. Mukaiyama, et al.
Disturbance of the Growth Hormone-Insulin-like Growth Factor-1 Axis Associated with Poor Performance Status in Patients with Solid Tumors
Jpn. J. Clin. Oncol., March 1, 2010; 40(3): 222 - 226.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. S. Gunturu, K. R. Meehan, T. A. Mackenzie, T. S. Crocenzi, D. McDermott, E. J. Usherwood, K. A. Margolin, N. A. Crosby, M. B. Atkins, M. J. Turk, et al.
Cytokine Working Group Study of Lymphodepleting Chemotherapy, Interleukin-2, and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma: Clinical Outcomes and Peripheral-Blood Cell Recovery
J. Clin. Oncol., March 1, 2010; 28(7): 1196 - 1202.
[Abstract] [Full Text] [PDF]

Home page
 DMMHome page
C. M. Contreras, E. A. Akbay, T. D. Gallardo, J. M. Haynie, S. Sharma, O. Tagao, N. Bardeesy, M. Takahashi, J. Settleman, K.-K. Wong, et al.
Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy
Dis. Model. Mech., March 1, 2010; 3(3-4): 181 - 193.
[Abstract] [Full Text] [PDF]

Home page
 J Child Health CareHome page
L. A. Long, D. L. Wodrich, R. Levy, M. M. Etzl Jr, and A. T. Gieseking
Students with brain tumors: their post-treatment perceptions of teachers, peers, and academics and retrospective views on school during treatment
J Child Health Care, March 1, 2010; 14(1): 111 - 125.
[Abstract] [PDF]

Home page
 Ann OncolHome page
J. A. Treat, R. Gonin, M. A. Socinski, M. J. Edelman, R. B. Catalano, D. M. Marinucci, R. Ansari, H. H. Gillenwater, K. M. Rowland, R. L. Comis, et al.
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer
Ann. Onc., March 1, 2010; 21(3): 540 - 547.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. Beck, H. B. Urnovitz, W. M. Mitchell, and E. Schutz
Next Generation Sequencing of Serum Circulating Nucleic Acids from Patients with Invasive Ductal Breast Cancer Reveals Differences to Healthy and Nonmalignant Controls
Mol. Cancer Res., March 1, 2010; 8(3): 335 - 342.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Huang, M. Menefee, M. Edgerly, S. Zhuang, H. Kotz, M. Poruchynsky, L. M. Huff, S. Bates, and T. Fojo
A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma
Clin. Cancer Res., March 1, 2010; 16(5): 1634 - 1641.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. S. Sikandar, K. T. Pate, S. Anderson, D. Dizon, R. A. Edwards, M. L. Waterman, and S. M. Lipkin
NOTCH Signaling Is Required for Formation and Self-Renewal of Tumor-Initiating Cells and for Repression of Secretory Cell Differentiation in Colon Cancer
Cancer Res., February 15, 2010; 70(4): 1469 - 1478.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Michels, S. L. Ellard, L. Le, C. Kollmannsberger, N. Murray, E. S. Tomlinson Guns, R. Carr, and K. N. Chi
A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer
Ann. Onc., February 1, 2010; 21(2): 305 - 311.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. K. Thomsen, L. Ambroisine, S. Wynn, K. S.E. Cheah, C. S. Foster, G. Fisher, D. M. Berney, H. Moller, V. E. Reuter, P. Scardino, et al.
SOX9 Elevation in the Prostate Promotes Proliferation and Cooperates with PTEN Loss to Drive Tumor Formation
Cancer Res., February 1, 2010; 70(3): 979 - 987.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
A. S. Kierans, M. Elazzazi, L. Braga, P. Leonardou, D. A. Gerber, C. Burke, W. Qureshi, M. Kanematsu, and R. C. Semelka
Thermoablative Treatments for Malignant Liver Lesions: 10-Year Experience of MRI Appearances of Treatment Response
Am. J. Roentgenol., February 1, 2010; 194(2): 523 - 529.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
H. Kim, J. S. Lim, J. Y. Choi, J. Park, Y. E. Chung, M.-J. Kim, E. Choi, N. K. Kim, and K. W. Kim
Rectal Cancer: Comparison of Accuracy of Local-Regional Staging with Two- and Three-dimensional Preoperative 3-T MR Imaging
Radiology, February 1, 2010; 254(2): 485 - 492.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
J. Y. C. Chow, M. Ban, H. L. Wu, F. Nguyen, M. Huang, H. Chung, H. Dong, and J. M. Carethers
TGF-{beta} downregulates PTEN via activation of NF-{kappa}B in pancreatic cancer cells
Am J Physiol Gastrointest Liver Physiol, February 1, 2010; 298(2): G275 - G282.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Jimeno, B. Rubio-Viqueira, N.V. Rajeshkumar, A. Chan, A. Solomon, and M. Hidalgo
A Fine-Needle Aspirate-Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer
Mol. Cancer Ther., February 1, 2010; 9(2): 311 - 318.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Zhang, A. Singh, S. Yegnasubramanian, D. Esopi, P. Kombairaju, M. Bodas, H. Wu, S. G. Bova, and S. Biswal
Loss of Kelch-Like ECH-Associated Protein 1 Function in Prostate Cancer Cells Causes Chemoresistance and Radioresistance and Promotes Tumor Growth
Mol. Cancer Ther., February 1, 2010; 9(2): 336 - 346.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. L. Wong, P. B. Mangu, M. A. Choti, T. S. Crocenzi, G. D. Dodd III, G. S. Dorfman, C. Eng, Y. Fong, A. F. Giusti, D. Lu, et al.
American Society of Clinical Oncology 2009 Clinical Evidence Review on Radiofrequency Ablation of Hepatic Metastases From Colorectal Cancer
J. Clin. Oncol., January 20, 2010; 28(3): 493 - 508.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. M. Clough-Gorr, A. E. Stuck, S. S. Thwin, and R. A. Silliman
Older Breast Cancer Survivors: Geriatric Assessment Domains Are Associated With Poor Tolerance of Treatment Adverse Effects and Predict Mortality Over 7 Years of Follow-Up
J. Clin. Oncol., January 20, 2010; 28(3): 380 - 386.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. A. Stidley, M. A. Picchi, S. Leng, R. Willink, R. E. Crowell, K. G. Flores, H. Kang, T. Byers, F. D. Gilliland, and S. A. Belinsky
Multivitamins, Folate, and Green Vegetables Protect against Gene Promoter Methylation in the Aerodigestive Tract of Smokers
Cancer Res., January 15, 2010; 70(2): 568 - 574.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L.-E Wang, Z. Hu, E. M. Sturgis, M. R. Spitz, S. S. Strom, C. I. Amos, Z. Guo, Y. Qiao, A. M. Gillenwater, J. N. Myers, et al.
Reduced DNA Repair Capacity for Removing Tobacco Carcinogen-Induced DNA Adducts Contributes to Risk of Head and Neck Cancer but not Tumor Characteristics
Clin. Cancer Res., January 15, 2010; 16(2): 764 - 774.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. M. Roe, A. L. Fitzpatrick, C. Xiong, W. Sieh, L. Kuller, J. P. Miller, M. M. Williams, R. Kopan, M. I. Behrens, and J. C. Morris
Cancer linked to Alzheimer disease but not vascular dementia
Neurology, January 12, 2010; 74(2): 106 - 112.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. A. Reed, C. N. Mayhew, A. K. McClendon, and E. S. Knudsen
Unique Impact of RB Loss on Hepatic Proliferation: TUMORIGENIC STRESSES UNCOVER DISTINCT PATHWAYS OF CELL CYCLE CONTROL
J. Biol. Chem., January 8, 2010; 285(2): 1089 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Genomics ProteomicsHome page
H. AL-HUMADI, A. ZARROS, R. AL-SAIGH, and C. LIAPI
Genetic Basis and Gene Therapy Trials for Thyroid Cancer
Cancer Genomics Proteomics, January 1, 2010; 7(1): 31 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. Strano, L. Ouafi, M. Baud, and M. Alifano
Primary Chordoma of the Lung.
Ann. Thorac. Surg., January 1, 2010; 89(1): 302 - 303.
[Abstract] [Full Text] [PDF]

Home page
 Exp Biol MedHome page
G. Korpanty, E. Smyth, L. A Sullivan, R. A Brekken, and D. N Carney
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway
Exp Biol Med, January 1, 2010; 235(1): 3 - 9.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. T. Penson, D. S. Dizon, S. A. Cannistra, M. R. Roche, C. N. Krasner, S. T. Berlin, N. S. Horowitz, P. A. DiSilvestro, U. A. Matulonis, H. Lee, et al.
Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Mullerian Tumors
J. Clin. Oncol., January 1, 2010; 28(1): 154 - 159.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Yoshizawa, J. Fukuoka, S. Shimizu, K. Shilo, T. J. Franks, S. M. Hewitt, T. Fujii, C. Cordon-Cardo, J. Jen, and W. D. Travis
Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non-Small Cell Lung Cancer
Clin. Cancer Res., January 1, 2010; 16(1): 240 - 248.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
J.-W. Shin, C. Pancaro, C. F. Wang, and P. Gerner
The Effects of Resiniferatoxin in an Experimental Rat Thoracotomy Model
Anesth. Analg., January 1, 2010; 110(1): 228 - 232.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Pijls-Johannesma, J. P.C. Grutters, F. Verhaegen, P. Lambin, and D. De Ruysscher
Do We Have Enough Evidence to Implement Particle Therapy as Standard Treatment in Lung Cancer? A Systematic Literature Review
Oncologist, January 1, 2010; 15(1): 93 - 103.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. P. Quinn, S. T. Vadaparampil, J.-H. Lee, P. B. Jacobsen, G. Bepler, J. Lancaster, D. L. Keefe, and T. L. Albrecht
Physician Referral for Fertility Preservation in Oncology Patients: A National Study of Practice Behaviors
J. Clin. Oncol., December 10, 2009; 27(35): 5952 - 5957.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
A. Soeda, Y. Morita-Hoshi, H. Makiyama, C. Morizane, H. Ueno, M. Ikeda, T. Okusaka, S. Yamagata, N. Takahashi, I. Hyodo, et al.
Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer
Jpn. J. Clin. Oncol., December 1, 2009; 39(12): 797 - 806.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. L. Spector and K. L. Blackwell
Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
J. Clin. Oncol., December 1, 2009; 27(34): 5838 - 5847.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
C. Planque, V. Kulasingam, C. R. Smith, K. Reckamp, L. Goodglick, and E. P. Diamandis
Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines
Mol. Cell. Proteomics, December 1, 2009; 8(12): 2746 - 2758.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. M. Lyon, D. M. Klinge, K. C. Do, M. J. Grimes, C. L. Thomas, L. A. Damiani, T. H. March, C. A. Stidley, and S. A. Belinsky
Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model
Carcinogenesis, December 1, 2009; 30(12): 2095 - 2099.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Chanda, T. Isayeva, S. Kumar, J. A. Hensel, A. Sawant, G. Ramaswamy, G. P. Siegal, M. S. Beatty, and S. Ponnazhagan
Therapeutic Potential of Adult Bone Marrow-Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis
Clin. Cancer Res., December 1, 2009; 15(23): 7175 - 7185.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Genomics ProteomicsHome page
C.-S. Liu, C.-W. Tsai, T.-C. Hsia, R.-F. Wang, C.-J. Liu, L.-W. Hang, S.-Y. Chiang, C.-H. Wang, R.-Y. Tsai, C.-C. Lin, et al.
Interaction of Methylenetetrahydrofolate Reductase Genotype and Smoking Habit in Taiwanese Lung Cancer Patients
Cancer Genomics Proteomics, November 1, 2009; 6(6): 325 - 329.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
V. Jayaprakash, M. Sullivan, M. Merzianu, N. R. Rigual, T. R. Loree, S. R. Popat, K. B. Moysich, S. Ramananda, T. Johnson, J. R. Marshall, et al.
Autofluorescence-Guided Surveillance for Oral Cancer
Cancer Prevention Research, November 1, 2009; 2(11): 966 - 974.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
C. A. Deegan, D. Murray, P. Doran, P. Ecimovic, D. C. Moriarty, and D. J. Buggy
Effect of anaesthetic technique on oestrogen receptor-negative breast cancer cell function in vitro
Br. J. Anaesth., November 1, 2009; 103(5): 685 - 690.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
C. D. Johnson
CT Colonography: Coming of Age
Am. J. Roentgenol., November 1, 2009; 193(5): 1239 - 1242.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
E. Ito, K. W. Yip, D. Katz, S. B. Fonseca, D. W. Hedley, S. Chow, G. W. Xu, T. E. Wood, C. Bastianutto, A. D. Schimmer, et al.
Potential Use of Cetrimonium Bromide as an Apoptosis-Promoting Anticancer Agent for Head and Neck Cancer
Mol. Pharmacol., November 1, 2009; 76(5): 969 - 983.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. Moretti, D. S. Yu, H. Chen, D. P. Carbone, D. H. Johnson, V. L. Keedy, J. B. Putnam Jr., A. B. Sandler, Y. Shyr, and B. Lu
Prognostic Factors for Resected Non-Small Cell Lung Cancer with pN2 Status: Implications for Use of Postoperative Radiotherapy
Oncologist, November 1, 2009; 14(11): 1106 - 1115.
[Abstract] [Full Text] [PDF]

Home page
 Health Educ ResHome page
C. L. Holt, M. Shipp, M. Eloubeidi, K. S. Clay, M. A. Smith-Janas, M. J. Janas, K. Britt, M. Norena, and M. N. Fouad
Use of focus group data to develop recommendations for demographically segmented colorectal cancer educational strategies
Health Educ. Res., October 1, 2009; 24(5): 876 - 889.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
D. A. Troyer, M. S. Lucia, A. P. de Bruine, R. Mendez-Meza, M. M. Baldewijns, N. Dunscomb, M. Van Engeland, T. McAskill, K. Bierau, J. Louwagie, et al.
Prostate Cancer Detected by Methylated Gene Markers in Histopathologically Cancer-Negative Tissues from Men with Subsequent Positive Biopsies
Cancer Epidemiol. Biomarkers Prev., October 1, 2009; 18(10): 2717 - 2722.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Mancini, E. Vergara, G. Salvatore, A. Greco, G. Troncone, A. Affuso, R. Liuzzi, P. Salerno, M. Scotto di Santolo, M. Santoro, et al.
Morphological Ultrasound Microimaging of Thyroid in Living Mice
Endocrinology, October 1, 2009; 150(10): 4810 - 4815.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
L. Peng, Y.-L. Ran, H. Hu, L. Yu, Q. Liu, Z. Zhou, Y.-M. Sun, L.-C. Sun, J. Pan, L.-X. Sun, et al.
Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway
Carcinogenesis, October 1, 2009; 30(10): 1660 - 1669.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
T. Tsujikawa, Y. Yoshida, T. Kudo, Y. Kiyono, T. Kurokawa, M. Kobayashi, T. Tsuchida, Y. Fujibayashi, F. Kotsuji, and H. Okazawa
Functional Images Reflect Aggressiveness of Endometrial Carcinoma: Estrogen Receptor Expression Combined with 18F-FDG PET
J. Nucl. Med., October 1, 2009; 50(10): 1598 - 1604.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
Z. Syed, S. B. Cheepala, J. N. Gill, J. Stein, C. A. Nathan, J. DiGiovanni, V. Batra, P. Adegboyega, H. E. Kleiner, and J. L. Clifford
All-Trans Retinoic Acid Suppresses Stat3 Signaling during Skin Carcinogenesis
Cancer Prevention Research, October 1, 2009; 2(10): 903 - 911.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Oh, B. J. Stish, D. Sachdev, H. Chen, A. Z. Dudek, and D. A. Vallera
A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma
Clin. Cancer Res., October 1, 2009; 15(19): 6137 - 6147.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Ishiguro, K. Akimoto, Y. Nagashima, Y. Kojima, T. Sasaki, Y. Ishiguro-Imagawa, N. Nakaigawa, S. Ohno, Y. Kubota, and H. Uemura
aPKC{lambda}/{iota} promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6
PNAS, September 22, 2009; 106(38): 16369 - 16374.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Bellmunt, C. Theodore, T. Demkov, B. Komyakov, L. Sengelov, G. Daugaard, A. Caty, J. Carles, A. Jagiello-Gruszfeld, O. Karyakin, et al.
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
J. Clin. Oncol., September 20, 2009; 27(27): 4454 - 4461.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
G. L. Lu-Yao, P. C. Albertsen, D. F. Moore, W. Shih, Y. Lin, R. S. DiPaola, M. J. Barry, A. Zietman, M. O'Leary, E. Walker-Corkery, et al.
Outcomes of Localized Prostate Cancer Following Conservative Management
JAMA, September 16, 2009; 302(11): 1202 - 1209.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W.-Y. Kim, Q. Jin, S.-H. Oh, E. S. Kim, Y. J. Yang, D. H. Lee, L. Feng, C. Behrens, L. Prudkin, Y. E. Miller, et al.
Elevated Epithelial Insulin-like Growth Factor Expression Is a Risk Factor for Lung Cancer Development
Cancer Res., September 15, 2009; 69(18): 7439 - 7448.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M.-H. Lee, B. Y. Choi, J. K. Kundu, Y. K. Shin, H.-K. Na, and Y.-J. Surh
Resveratrol Suppresses Growth of Human Ovarian Cancer Cells in Culture and in a Murine Xenograft Model: Eukaryotic Elongation Factor 1A2 as a Potential Target
Cancer Res., September 15, 2009; 69(18): 7449 - 7458.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Krishnaswamy, R. Kanteti, J. S. Duke-Cohan, S. Loganathan, W. Liu, P. C. Ma, M. Sattler, P. A. Singleton, N. Ramnath, F. Innocenti, et al.
Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
Clin. Cancer Res., September 15, 2009; 15(18): 5714 - 5723.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. R. Epis, K. M. Giles, A. Barker, T. S. Kendrick, and P. J. Leedman
miR-331-3p Regulates ERBB-2 Expression and Androgen Receptor Signaling in Prostate Cancer
J. Biol. Chem., September 11, 2009; 284(37): 24696 - 24704.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Genomics ProteomicsHome page
F. E. Ahmed, C. D. Jeffries, P. W. Vos, G. Flake, G. J. Nuovo, D. R. Sinar, W. Naziri, and S. P. Marcuard
Diagnostic MicroRNA Markers for Screening Sporadic Human Colon Cancer and Active Ulcerative Colitis in Stool and Tissue
Cancer Genomics Proteomics, September 1, 2009; 6(5): 281 - 295.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
S. H. Blackmon, N. Shah, J. A. Roth, A. M. Correa, A. A. Vaporciyan, D. C. Rice, W. Hofstetter, G. L. Walsh, R. Benjamin, R. Pollock, et al.
Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival.
Ann. Thorac. Surg., September 1, 2009; 88(3): 877 - 884.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Freely available
Right arrow Submit a Comment to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when Comments are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jemal, A.
Right arrow Articles by Thun, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jemal, A.
Right arrow Articles by Thun, M. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH SEARCH RESULT